PHY2130: PMCF Study on Comparison of EDOF Lenses (Switzerland)

Sponsor
Beaver-Visitec International, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05235139
Collaborator
targomedGmbH (Industry)
68
1
2
15.7
4.3

Study Details

Study Description

Brief Summary

Single center, prospective, randomised, controlled, double-blind post-market clinical follow-up (PMCF) study to compare the clinical outcomes of a premium monofocal intraocular lens (PhysIOL ISOPURE 1.2.3.) with clinical data obtained in a control group implanted with an EDOF IOL (Alcon Acrysof IQ Vivity).

Condition or Disease Intervention/Treatment Phase
  • Device: IOL implantation experimental (ISOPURE 1.2.3.)
  • Device: IOL implantation active comparator (Acrysof Vivity)
N/A

Detailed Description

This is a single center, prospective, randomised, controlled, double-blind post-market clinical follow-up (PMCF) study whereby patients undergoing routine cataract surgery will have bilateral implantation of premium monofocal intraocular lenses (PhysIOL ISOPURE 1.2.3.) or EDOF lenses (Alcon Acrysof IQ Vivity). The patients will be randomized in a 1:1 ratio to receive the study or control lenses. Both IOLs, investigational device and control device, are CE approved and commercially available in the countries this clinical investigation is being carried out. The investigational device and all study products, including the devices used for the study examinations, will be used within the intended use specifications from the manufacturer. In addition, no invasive or other burdening examinations will occur for the patient.

The device under investigation (ISOPURE 1.2.3.) is a hydrophobic, glistening-free, acrylic premium monofocal intraocular lens (IOL) manufactured by the sponsor of this study, PhysIOL sa/nv. The control lens (Alcon Acrysof IQ Vivity) is a non-diffractive Extended Vision Posterior Chamber IOL.

The IOLs will be implanted as part of the routine cataract surgery on patients suffering from cataract development.

Subjects participating in the trial will attend a total of 6 study visits (1 preoperative, 1 operative and 4 postoperative) over a period of 6 months. Subjects would have the option for unscheduled visits if required medically.

Primary and secondary endpoint data will be collected at the 120-180 days follow up visit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
68 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
Double-blind masking; Patient will not be informed which IOL model was implanted until end of the study. Outcomes assessors will not be informed which IOL model was implanted until end of the study.
Primary Purpose:
Treatment
Official Title:
Prospective Post-Market Clinical Follow-Up (PMCF) Study to Investigate the Clinical Outcomes of a Premium Monofocal Intraocular Lens (IOL) in Comparison to an EDOF Lens
Actual Study Start Date :
Mar 9, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: IOL implantation experimental

Experimental arm: Premium monofocal intraocular lens.

Device: IOL implantation experimental (ISOPURE 1.2.3.)
Implantation of premium monofocal IOL ISOPURE 1.2.3.

Active Comparator: IOL implantation active comparator

Comparator arm: EDOF intraocular lens.

Device: IOL implantation active comparator (Acrysof Vivity)
Implantation of EDOF IOL Acrysof Vivity

Outcome Measures

Primary Outcome Measures

  1. monocular Best Corrected Distance Visual Acuity (CDVA) under photopic light conditions on the first implanted eye. [6 months (120-180 days) postoperative]

    Non inferiority of ISOPURE 1.2.3. outcomes compared to the Acrysof IQ Vivity outcomes in terms of monocular Best Corrected Distance Visual Acuity (CDVA) by means of statistical significance. A significance level of 0.05 or lower (p < 0.05) will be considered statistically significant. CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2018.

Secondary Outcome Measures

  1. Safety (Rates of Adverse Events) [1 day (1-2 days) postoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The objective is to compare the SPE (Safety and Performance Endpoints) rates of the investigational product to the results of historical data of EN ISO 11979-7:2018, Annex E (Table E.2)

Other Outcome Measures

  1. Intraocular pressure (IOP) measurement [Preoperative, 1 day (1-2 days) postoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The IOP will be measured with non-contact tonometer as part of the routine follow up examinations. The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  2. Keratometry [Preoperative]

    Keratometric measurements are performed to calculate the required IOL power. The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  3. IOL power [Operative (day of surgery)]

    The IOL spherical power of the implanted IOL must be recorded.

  4. Target refraction [Operative (day of surgery)]

    The target refraction given by the IOL calculator must be recorded. This parameter is needed to calculate the accuracy of achieving the target refraction. The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  5. Fundus OCT [Preoperative, 1 month (30-60 days) postoperative]

    An OCT (optical coherence tomography) image will be taken at the preoperative visit and 1 months postoperative visit to identify AMD suspicious eyes that need to be excluded from this study. The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  6. Pupil Size under photopic light conditions [preoperative]

    Photopic pupil diameters are measured with a precision of at least +/-0.5 mm. For the photopic pupil diameters, eye illumination should be identical to that used for photopic contrast sensitivity testing. It is required that pupil measurements be made with an infrared pupillometer / CCD camera. Pupil measurements should only be made after the eye has had time to fully adapt to the testing conditions (at least 10 minutes). The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  7. Pupil Size under mesopic light conditions [preoperative]

    Mesopic pupil diameters are measured with a precision of at least +/-0.5 mm. For the mesopic pupil diameters, eye illumination should be identical to that used for mesopic contrast sensitivity testing. It is required that pupil measurements be made with an infrared pupillometer / CCD camera. Pupil measurements should only be made after the eye has had time to fully adapt to the testing conditions (at least 10 minutes). The examination is performed and documented according to the guidelines in ISO 11979-7:2018.

  8. Manifested refraction [Preoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The manifested refraction is measured by means of a phoropter. The data contains values for sphere, cylinder and axis of cylinder according to ISO 11979-7:2018. This data will also be used to calculate the manifested refractive spherical equivalent (MRSE)

  9. Monocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions [Preoperative, 1 day (1-2 days) postoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    monocular UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2018. This assessment is done monocularly under photopic light conditions.

  10. Binocular Uncorrected Distance Visual Acuity (UDVA) under photopic light conditions [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Binocular UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2018. This assessment is done binocularly under photopic light conditions.

  11. Binocular Uncorrected Distance Visual Acuity (UDVA) under mesopic light conditions [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Binocular UDVA is measured with ETDRS charts placed in 4m distance according to ISO 11979-7:2018. This assessment is done binocularly under mesopic light conditions.

  12. Monocular Corrected Distance Visual Acuity (CDVA) under photopic light conditions [Preoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Monocular CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2018. This assessment is done monocularly under photopic light conditions.

  13. Binocular Corrected Distance Visual Acuity (CDVA) under photopic light conditions [6 months (120-180 days) postoperative]

    Binocular CDVA is measured with ETDRS charts placed in 4m distance with best aided corrective glasses according to ISO 11979-7:2018. This assessment is done binocularly under photopic light conditions.

  14. Monocular Distance Corrected Intermediate Visual Acuity at 66cm (DCIVA@66cm) under photopic light conditions [1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Monocular DCIVA@66cm is measured with ETDRS charts placed in 66cm distance with corrective glasses for far distance according to ISO 11979-7:2018. This assessment is done monocularly under photopic light conditions.

  15. Binocular Uncorrected Intermediate Visual Acuity at 66cm (UIVA@66cm) under photopic light condition [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Binocular UIVA@66cm is measured with ETDRS charts placed in 66cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2018. This assessment is done binocularly under photopic light conditions.

  16. Binocular Uncorrected Intermediate Visual Acuity at 66cm (UIVA@66cm) under mesopic light condition [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Binocular UIVA@66cm is measured with ETDRS charts placed in 66cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2018. This assessment is done binocularly under mesopic light conditions.

  17. Monocular Distance Corrected Near Visual Acuity at 40cm (DCNVA) under photopic light conditions [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Monocular DCNVA is measured with ETDRS charts placed in 40cm distance with corrective glasses for far distance according to ISO 11979-7:2018. This assessment is done monocularly under photopic light conditions.

  18. Binocular Uncorrected Near Visual Acuity at 40cm (UNVA) under photopic light conditions [1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    Monocular UNVA is measured with ETDRS charts placed in 40cm distance. The examination is done without corrective glasses and according to ISO 11979-7:2018. This assessment is done binocularly under photopic light conditions.

  19. Binocular Defocus Curve [1 month (30-60 days) postoperative]

    To assess the visual acuity for different distances, defocus curves under photopic light conditions are measured. This test is performed with best distance corrected refraction and spherical additions ranging from -2.5 D to +1.5 D in 0.5 D steps. This examination is performed binocularly.

  20. Binocular Contrast Sensitivity under photopic light conditions [6 months (120-180 days) postoperative]

    Contrast Sensitivity under photopic light conditions using the standardized contrast sensitivity device CSV-1000 (Vector Vision). This examination is performed binocularly.

  21. Binocular Contrast Sensitivity under mesopic light conditions [6 months (120-180 days) postoperative]

    Contrast Sensitivity under mesopic light conditions using the standardized contrast sensitivity device CSV-1000 (Vector Vision). This examination is performed binocularly.

  22. Slitlamp examination - Corneal status [Preoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: • Corneal Status

  23. Slitlamp examination - Signs of inflammation [Preoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - Signs of inflammation

  24. Slitlamp examination - Iris status [Preoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - Iris status

  25. Fundus examination with dilated pupil [Preoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: • Fundus

  26. Slitlamp examination - Optic nerve cupping [Preoperative, 1 week (7-14 days) postoperative, 1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative, 12 months (330-420 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - Optic nerve cupping

  27. Slitlamp examination - Posterior Capsular Opacification (PCO) or Posterior Capsular Fibrosis [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - Posterior Capsular Opacification (PCO) or Posterior Capsular Fibrosis

  28. Slitlamp examination - IOL discoloration [6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - IOL discoloration.

  29. Slitlamp examination - abnormal IOL positioning [1 month (30-60 days) postoperative, 6 months (120-180 days) postoperative]

    The slitlamp examination is one examination to analyse the integrity of eye structures and the implanted IOL. The examination is performed and documented according to the guidelines in ISO 11979-7:2018. With the slitlamp the ophthalmologist can observe the eyes stereoscopically. A focussed slit of light, which can be width-adjusted, is projected on the eye to be examined. The investigator observes this projection on the eye through a reflected light microscope. The slitlamp is used to observe the anterior and posterior part of the eye, including cornea, lens and anterior chamber. By dilating the pupil the fundus can also be examined. Following conditions shall be examined with the slitlamp: - abnormal IOL positioning

  30. Patient reported outcomes - Quality of Vision questionnaire [McAlinden et al, 2010] [6 months (120-180 days) postoperative]

    To assess the subjective perception of disturbances by photic phenomena, the validated and verified Quality of Vision (QoV) questionnaire will be used. This questionnaire is a linear-scaled 30-item instrument and is designed with 10 symptoms rated in each of three scales (frequency, severity, and bothersome). The QoV Questionnaire provides a QoV score in terms of symptom frequency, severity, and bothersome [McAlinden et al, 2010].

  31. Patient reported outcomes - Patient-Reported Spectacle Independence Questionnaire (PRSIQ) [Morlock et al, 2017] [6 months (120-180 days) postoperative]

    The Patient-Reported Spectacle Independence Questionnaire (PRSIQ) is a patient-reported measure assessing spectacle independence following cataract surgery. The analyses conducted provide evidence for the use of the PRSIQ total score as a measure of spectacle independence [Morlock et al, 2017]. In the first category, subjects are asked if they need glasses for distance vision, intermediate vision and near vision with 'yes' and 'no' being the only possible answers. In the second category, patients are asked to scale their frequency of using spectacles over the last 7 days for three different distances with 5 ratings ranging from '1: All of the time' to '5: None of the time'. A higher rating means higher rate of spectacle independence. In addition, patients are asked to scale if they are able to function without spectacle aid for three different distances with 5 ratings ranging from '1: All of the time' to '5: None of the time'. A higher rating means higher rate of spectacle freedom.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Cataractous eyes with no comorbidity;

  • Calculated IOL power is within the range of the study IOLs;

  • Male or female adults ages 50 years or older on the day of screening who have cataract(s) in one or both eyes;

  • Regular total corneal astigmatism ≤1.0 D (measured by topography method)

  • Clear intraocular media other than cataract;

  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures;

  • Expected postoperative Best Corrected Distance Visual Acuity (CDVA) ≤ 0.2 logMAR;

  • Signed informed consent.

Exclusion Criteria:
  • Age of patient < 50 years;

  • Regular total corneal astigmatism >1.0 dioptres (measured by topography method)

  • Irregular astigmatism;

  • Difficulty for cooperation (distance from their home, general health conditions);

  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders);

  • Subjects who may be expected to require retinal laser treatment during the course of the study or at a greater risk of developing cystoid macular edema or macula pucker;

  • Previous intraocular or corneal surgery or intravitreal injection;

  • Traumatic cataract;

  • History or presence of macular edema;

  • Glaucoma with visual field defects;

  • Pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic / scotopic conditions);

  • Amblyopia with monocular preoperative CDVA of >0.1 logMAR;

  • Cornea guttata;

  • Keratoconus;

  • Chronic uveitis;

  • Expected complicated surgery;

  • Significant dry eye;

  • Contra-indications as listed in the current Instructions for use (IFU);

  • Contra-indication or unwillingness to perform immediate sequential bilateral cataract surgery;

  • Concurrent or previous (within 60 days) participation in another drug or device investigation.

In addition to above mentioned in- and exclusion criteria, subjects shall be discontinued when certain conditions are present at the time of surgery, including:

  • zonular instability or defect;

  • capsular fibrosis or other opacity; and

  • inability to fixate IOL in desired position. In such cases, the subject shall be followed until the condition has stabilized.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Eye center Vista Alpina Visp Switzerland 3930

Sponsors and Collaborators

  • Beaver-Visitec International, Inc.
  • targomedGmbH

Investigators

  • Principal Investigator: Kristof Vandekerkchove, MD, Eye center Vista Alpina

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Beaver-Visitec International, Inc.
ClinicalTrials.gov Identifier:
NCT05235139
Other Study ID Numbers:
  • PHY2130
First Posted:
Feb 11, 2022
Last Update Posted:
Jun 6, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Beaver-Visitec International, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 6, 2022